Asia Alternatives has reached a final close of USD 2bn for its sixth private equity fund-of-funds and several related vehicles. It is the firm’s largest raise since its inception in 2015.
Private equity exit timelines were thrown into disarray last year when US IPOs abruptly stopped. Regulators have offered some clarity, but investors are unsure when – or if – the magic will return
In leading a USD 82m cross-currency restructuring of a consumer-tech portfolio managed by China’s Bright Capital, Foundation Private Equity opted for a structure that is unusual yet prioritises alignment
China-based medical technology start-up SiBionics has raised CNY 500m (USD 79m) in a third tranche of Series C funding co-led by CPE and China Life Investment.
Shoplazza, a China-based software-as-a-service (SaaS) provider specialising in cross-border e-commerce, has raised USD 150m in the first tranche of Series C led by SoftBank Vision Fund II.
China’s River Head Capital has achieved a first close on its second Innovation Growth Fund, a renminbi-denominated vehicle that has an overall target of CNY 2bn (USD 135m).
Sequoia Capital China has raised a new economy infrastructure fund – which will invest in the likes of logistics, data centres, and life science parks – with Brookfield serving as the largest LP.
Harmay, a China-based omnichannel beauty products retailer, has raised USD 200m across Series C and D rounds.
A rebound in China-based activity took Asia private equity investment to a record USD 105.3bn in the fourth quarter, ensuring that 2021 represents a new high watermark for the industry.
Dishangtie Car Rental, a Shenzhen-based electric vehicle (EV) rental service, has raised a USD 200m Series D round across two tranches featuring CICC Capital.
The Chinese manufacturer of plant-based protein replacements has secured USD 100m in funding to advance a product portfolio that aspires to diversity and structural sophistication
China rebounds as Asia private equity investment ends 2021 with a bang; bright spots in improving fundraising environment; sponsor-to-sponsor exits thrive while PE-backed IPOs stumble
Blockchain, hardware, and entrepreneurs going global are on the agenda for Ince Capital Partners’ second fund, which closed above target despite LPs getting spooked by the tech sector crackdown
Policy volatility in China has prompted many investors to eschew consumer-facing business models in favour of B2B plays like deep-tech, but sector specialists still see opportunity, the Hong Kong Venture Capital & Private Equity Association’s (HKVCA)...
SoftBank Vision Fund II has led a CNY 1bn (USD 157m) Series C for Shanghai-based chipmaker Eigencomm, with participation from new investors Cathay Capital, CoStone Capital, Chobe Capital, and GF Qianhe, a unit of GF Securities.
A private equity consortium pursuing a take-private of US-listed Chinese online recruitment platform 51job has cut its offer price by 28%, citing deteriorating market conditions, regulatory tightening in China, and the continuing impact of COVID-19.
Primavera Capital Group has led a USD 100m Series B for Starfield, a Chinese producer of plant-based meats.
Bluepha, a China-based synthetic biology company working on a range of biodegradable plastics, has raised a three-tranche Series B of CNY 1.5bn (USD 235m).
Goldman Sachs Asset Management and Sofina have led a USD 100m Series C round for Zhenge Biotech, a Shanghai-based contract development and manufacturing organisation (CDMO).
As a supply chain specialist, Eastern Bell Capital claims to have a differentiated take on China industrial digitalisation. It has USD 800m in dry powder to prove this thesis
FountainVest Partners has acquired China F&B Group (CFB), one of the master franchise operators for Papa John’s and Dairy Queen in mainland China, from EQT for an undisclosed sum.
Advantech Capital has led a USD 60m Series B for Suzhou-based biotech player Cure Genetics. Other investors include Oriza Holdings, Blue Ocean Private Equity, and Qiming Venture Partners.